Free Trial
NASDAQ:APGE

Apogee Therapeutics (APGE) Stock Price, News & Analysis

Apogee Therapeutics logo
$52.04
-2.86 (-5.21%)
(As of 05:16 PM ET)

About Apogee Therapeutics Stock (NASDAQ:APGE)

Key Stats

Today's Range
$50.48
$54.72
50-Day Range
$46.95
$59.92
52-Week Range
$14.19
$72.29
Volume
469,791 shs
Average Volume
495,706 shs
Market Capitalization
$3.04 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$78.50
Consensus Rating
Buy

Company Overview

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Apogee Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
54th Percentile Overall Score

APGE MarketRank™: 

Apogee Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 565th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Apogee Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Apogee Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Apogee Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Apogee Therapeutics are expected to decrease in the coming year, from ($2.57) to ($3.02) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Apogee Therapeutics is -25.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Apogee Therapeutics is -25.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Apogee Therapeutics has a P/B Ratio of 6.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Apogee Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    18.90% of the float of Apogee Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Apogee Therapeutics has a short interest ratio ("days to cover") of 17.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Apogee Therapeutics has recently decreased by 4.98%, indicating that investor sentiment is improving.
  • Dividend Yield

    Apogee Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Apogee Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    18.90% of the float of Apogee Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Apogee Therapeutics has a short interest ratio ("days to cover") of 17.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Apogee Therapeutics has recently decreased by 4.98%, indicating that investor sentiment is improving.
  • News Sentiment

    Apogee Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Apogee Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    3 people have searched for APGE on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Apogee Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Apogee Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,058,635.00 in company stock.

  • Percentage Held by Insiders

    36.10% of the stock of Apogee Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    79.04% of the stock of Apogee Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Apogee Therapeutics' insider trading history.
Receive APGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apogee Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APGE Stock News Headlines

War on Elon Escalates…
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
Apogee Therapeutics, Inc. (APGE) Gets a Buy from BTIG
Apogee Therapeutics price target raised to $100 from $81 at BTIG
Apogee Therapeutics, Inc. (APGE) Gets a Buy from TD Cowen
Wedbush Reaffirms Outperform Rating for Apogee Therapeutics (NASDAQ:APGE)
See More Headlines

APGE Stock Analysis - Frequently Asked Questions

Apogee Therapeutics' stock was trading at $27.94 at the beginning of the year. Since then, APGE shares have increased by 86.3% and is now trading at $52.04.
View the best growth stocks for 2024 here
.

Apogee Therapeutics, Inc. (NASDAQ:APGE) issued its quarterly earnings data on Monday, August, 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.60).

Apogee Therapeutics (APGE) raised $282 million in an IPO on Friday, July 14th 2023. The company issued 17,650,000 shares at $15.00-$17.00 per share.

Apogee Therapeutics' top institutional investors include Waypoint Capital Advisors LLC (1.07%), Handelsbanken Fonder AB (0.02%), China Universal Asset Management Co. Ltd. (0.01%) and AlphaCentric Advisors LLC (0.01%). Insiders that own company stock include Nimish P Shah, Michael Thomas Henderson, Carl Dambkowski and Jane Henderson.
View institutional ownership trends
.

Shares of APGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Apogee Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), Netflix (NFLX) and Invesco QQQ (QQQ).

Company Calendar

Last Earnings
8/12/2024
Today
10/31/2024
Next Earnings (Estimated)
11/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:APGE
Fax
N/A
Employees
91
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$78.50
High Stock Price Target
$95.00
Low Stock Price Target
$43.00
Potential Upside/Downside
+50.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-83,990,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.50 per share

Miscellaneous

Free Float
28,754,000
Market Cap
$3.04 billion
Optionable
Optionable
Beta
2.75
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

This page (NASDAQ:APGE) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners